{"entity":{"id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of DT-7012 in advanced solid tumours, run by Domain Therapeutics Australia Pty Ltd, now recruiting.","summary":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06819735 by Domain Therapeutics Australia Pty Ltd, with 125 participants planned, started 2025-06-25 and due to reach its primary completion in 2027-09. Interventions recorded: DT-7012 and Immune checkpoint inhibitor.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06819735","url":"https://clinicaltrials.gov/study/NCT06819735"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06819735","phase":"1/2","setting":"A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (DOMISOL, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)","sponsor":"Domain Therapeutics Australia Pty Ltd","enrolled":125,"outcomes":[]},"route":"/trials/nct06819735/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}